Neurocognitive Disorders Clinical Trials in Southampton
2 recruitingSouthampton, United Kingdom
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes
Neurocognitive Disorders
University of Manitoba225 enrolled10 locationsNCT05754567